First Trust Advisors LP Prothena Corp Public LTD CO Transaction History

First Trust Advisors LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$47.3 - $70.6 $1.45 Million - $2.17 Million	30,709 New	30,709 $1.48 Million
Q1 2023 May 15, 2023	SELL	$46.97 - $58.27 $1.94 Million - $2.41 Million	-41,288 Reduced 66.17%	21,108 $1.02 Million
Q4 2022 Feb 09, 2023	BUY	$52.05 - $65.0 $1.23 Million - $1.53 Million	23,588 Added 60.78%	62,396 $3.76 Million
Q3 2022 Nov 14, 2022	SELL	$25.16 - $60.63 $123,460 - $297,511	-4,907 Reduced 11.22%	38,808 $2.35 Million
Q2 2022 Aug 12, 2022	SELL	$22.73 - $39.98 $121,650 - $213,972	-5,352 Reduced 10.91%	43,715 $1.19 Million
Q1 2022 May 13, 2022	SELL	$30.27 - $49.22 $850,011 - $1.38 Million	-28,081 Reduced 36.4%	49,067 $1.79 Million
Q4 2021 Feb 08, 2022	BUY	$42.11 - $73.26 $3.25 Million - $5.65 Million	77,148 New	77,148 $3.81 Million
Q1 2018 Apr 23, 2018	SELL	$27.95 - $45.04 $734,665 - $1.18 Million	-26,285 Closed	0 $0
Q4 2017 Feb 08, 2018	BUY	$35.44 - $63.76 $815,757 - $1.47 Million	23,018 Added 704.56%	26,285 $985,000
Q3 2017 Oct 24, 2017	BUY	$53.83 - $67.75 $175,862 - $221,339	3,267	3,267 $212,000

198

44.5M

601K

259K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $701M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of First Trust Advisors LP, based on Form 13F filings with the SEC.

Stay updated on First Trust Advisors LP with notifications on news.